299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

diseases per page:

Showing 1 to 10 of 1,695 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05408910 (ClinicalTrials.gov)	July 2023	2/6/2022	Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis	Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis	Cystic Fibrosis;Abdominal Pain;Small Bowel Disease	Drug: Rifaximin 550 MG Oral Tablet [XIFAXAN];Drug: Placebo	Wake Forest University Health Sciences	Emory University;University of Minnesota;University of Texas Southwestern Medical Center	Not yet recruiting	12 Years	N/A	All	100	Phase 2/Phase 3	United States
2	NCT05344508 (ClinicalTrials.gov)	June 30, 2023	6/4/2022	An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic FibrosisBronchiectas ...	Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis	Non-Cystic Fibrosis Bronchiectasis	Drug: Brensocatib	Insmed Incorporated	NULL	Available	18 Years	85 Years	All			NULL
3	NCT05663255 (ClinicalTrials.gov)	March 1, 2023	15/12/2022	Effectiveness of CFTR Modulators According to Co-therapy	Is Effectiveness of CFTR (Cystic FibrosisTransmembrane Conductance Regulator) Modulators Impacted by ...	Cystic Fibrosis	Drug: Discontinuation of respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)	Hospices Civils de Lyon	NULL	Not yet recruiting	6 Years	N/A	All	1990		NULL
4	NCT05740618 (ClinicalTrials.gov)	March 1, 2023	3/2/2023	Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis	Effect of Bronchitol on Mucociliary Clearance in Cystic FibrosisTransmembrane Conductance Regulator ...	Cystic Fibrosis	Drug: Mannitol Inhalant Product	University of North Carolina, Chapel Hill	Chiesi USA, Inc.	Not yet recruiting	18 Years	N/A	All	25	Phase 4	United States
5	NCT05704036 (ClinicalTrials.gov)	March 2023	10/1/2023	Estrogen Patches for Adolescent and Young Adult Women With Cystic Fibrosis	Transdermal Estradiol for Adolescent and Young Adult Women With CF	Cystic Fibrosis;Hypoestrogenism	Drug: Transdermal estrogen;Drug: Placebo patch;Drug: Progesterone;Drug: Placebo pill	Johns Hopkins University	Cystic Fibrosis Foundation	Recruiting	16 Years	30 Years	Female	75	Phase 4	United States
6	NCT05668741 (ClinicalTrials.gov)	February 27, 2023	19/12/2022	A Phase 1 Study of VX-522 in Participants With Cystic Fibrosis (CF)	A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects ...	Cystic Fibrosis	Drug: VX-522 mRNA therapy	Vertex Pharmaceuticals Incorporated	NULL	Recruiting	18 Years	65 Years	All	9	Phase 1	United States
7	NCT05581056 (ClinicalTrials.gov)	February 24, 2023	12/10/2022	Evaluation of the Evolution of Quality of Life in Relation to Naso-sinus Symptomatology Under Treatm ...	Evaluation of the Evolution of Quality of Life in Relation to Naso-sinus Symptomatology Under Treatm ...	Cystic Fibrosis	Drug: CFTR modulators	Hospices Civils de Lyon	NULL	Not yet recruiting	6 Years	11 Years	All	90		France
8	NCT05712538 (ClinicalTrials.gov)	February 15, 2023	26/1/2023	Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects	A Phase 1 Randomized, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, ...	Cystic Fibrosis	Drug: ARCT-032;Other: Placebo	Arcturus Therapeutics, Inc.	Novotech CRO	Not yet recruiting	18 Years	65 Years	All	32	Phase 1	New Zealand
9	NCT05641298 (ClinicalTrials.gov)	February 10, 2023	29/11/2022	Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic FibrosisPulm ...	A Phase 2, Randomized, DB, Placebo-controlled Study to Determine the Efficacy, Safety and PK Profile ...	Cystic Fibrosis;Cystic Fibrosis Pulmonary Exacerbation	Drug: Sodium Fusidate;Drug: Placebo	Aceragen	NULL	Recruiting	12 Years	N/A	All	80	Phase 2	United States
10	NCT05548283 (ClinicalTrials.gov)	February 1, 2023	16/9/2022	Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study	Standardizing Treatments for Pulmonary Exacerbations: A Platform for Evaluating Treatment Decisions ...	Cystic Fibrosis;Cystic Fibrosis Pulmonary Exacerbation	Drug: Beta-lactam antibiotic;Drug: Aminoglycoside	Chris Goss	University of Washington;Medical University of South Carolina;Cystic Fibrosis Foundation	Not yet recruiting	6 Years	N/A	All	730	Phase 4	NULL

First Previous1 2 3 4 5…170Next Last